Moreover, elevated levels of MASTL protein correlate with poor disease outcome, and may have prognostic value in Estrogen Receptor (ER)-positive breast tumors independently of the Ki67 proliferation marker. This evidence concerns the gene ESR1 and breast neoplasm.